Prednisolone acetate ophthalmic suspension 1% is a sterile, topical anti-inflammatory agent for ophthalmic use and is ...

Key complex product approval in the Affordable Medicines segment this yearCommercial launch planned for third quarter of 2025 BRIDGEWATER, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceutical ...

Prednisolone acetate ophthalmic suspension is indicated for treating steroid-responsive ocular inflammation. Amneal plans to launch the product in the third quarter of 2025.

Key complex product approval in the Affordable Medicines segment this yearCommercial launch planned for third quarter of 2025 ...

Prednisolone acetate ophthalmic suspension, USP 1% is a sterile, topical anti-inflammatory agent for ophthalmic use and is indicated for treating steroid-responsive ocular inflammation.

Key complex product approval in the Affordable Medicines segment this year; Commercial launch planned for third quarter of 2025; BRIDGEWATER, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- Amneal ...

BRIDGEWATER, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) today announced the U.S. Food and Drug Administration (FDA) approval of ...

Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension. Amneal Pharmaceuticals LLC - (GLOBE NEWSWIRE) Jun 12, 2025 Jun 12, 2025; Facebook; Twitter; ...

Johnson & Johnson (NYSE:JNJ) said on Tuesday that niraparib, a cancer treatment from a group of drugs called PARP inhibitors, successfully met its main goal in a Phase 3 trial for prostate cancer when ...

Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double ...

What we found is that the combination of niraparib, abiraterone acetate, and prednisone is achieving just that, with the goal of offering patients precious quality time before the disease enters a ...